Supplementary Material

Comparison of Different Durations of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis

Dae Yong Park*, MD[a]; Jiun-Ruey Hu*, MPH, MD[b], Greta Campbell[c], Kiara Goldwag, MSN[b]; Michelle D. Kelsey, MD[d]; S. Elissa Altin, MD[b], Cesia Gallegos-Kattán, MD, MHS[b], Michael G. Nanna, MD, MHS[b]

*These two authors equally contributed to this study.

[a] Department of Medicine, Cook County Health, Chicago, IL, USA

[b] Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA

[c] Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA

[d] Department of Medicine, Division of Cardiology, Duke University, Durham, NC, USA

Email of correspondence author: michael.nanna@yale.edu

Supplemental Table S1. PRISMA 2020 checklist

Topic	No.	Item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	LN 1-3
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist	Table S1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	LN 68-83
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	LN 84-87
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	LN 97-118
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	LN 98-99
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Table S2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	LN 113-118
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	LN 121-126
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	LN 121-126

Topic	No.	Item	Location where item is reported
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	LN 121-126
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	LN 117-118
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	LN 124-126
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item 5)).	LN 129-138
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	LN 129-132
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	LN 131-139
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	LN 129-148
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	LN 134-135
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	LN 139-146
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	LN 117-118
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	LN 117-118
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	LN 151-152, Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Table 1, Table S3
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S5

Topic	No.	Item	Location where item is reported
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Table 2
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Table 1, Table S5
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	LN 179-193
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	LN 174-178, Table S7
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	LN 194-201, Table S9-S11
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Table S5
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	LN 173-174, Table S6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	LN 204-217
	23b	Discuss any limitations of the evidence included in the review.	LN 283-300
	23c	Discuss any limitations of the review processes used.	LN 283-300
	23d	Discuss implications of the results for practice, policy, and future research.	LN 301-307
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	LN 91
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	LN 91
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	LN 314
Competing interests	26	Declare any competing interests of review authors.	LN 22-33

Topic	No.	Item	Location where item is reported
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	LN 317

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv. 2020, September 14. DOI: 10.31222/osf.io/v7gm2. For more information, visit: www.prisma-statement.org8

PRISMA Abstract Checklist

Topic	No.	Item	Reported?
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesize results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			

Topic	No.	Item	Reported?
Funding	11	Specify the primary source of funding for the review.	Yes
Registration	12	Provide the register name and registration number.	Yes

Supplemental Table S2. Search strategy used in this study

Database	Search Strategy
Cochrane Library	#1 ((duration or length or timing or time or months or reduce* or alterat*) near/3 (dose* or therapy* or treatment* or medication* or DAPT or "dual anti-platelet")):ti,ab OR (de-escalat* or "prescribing practice*" or short-term or abbreviat*):ti,ab OR (duration or length or timing or time or month*):ti #2 ((antiplatelet or anti-platelet) near/3 (dual or combination) near/3 (intervention* or therap*)):ti,ab or ((Aspirin or "Acetylsalicylic acid") and (clopidogrel or plavix or prasugrel or effient or ticagrelor or brilinta or "P2Y12 inhibitor*")):ti,ab or (DAPT):ti,ab #3 ("percutaneous coronary" near/3 (interven* or revascular*)):ti,ab or (PCI):ti,ab or ((balloon or stent*) near/3 angioplast*):ti,ab or (("drug coated" or "drug eluting" or "drug releasing") near/3 stent*):ti,ab #4 #1 and #2 and #3
Ovid Embase	1 exp percutaneous coronary intervention/ 2 exp drug eluting stent/ 3 (percutaneous coronary adj3 (interven* or revascular*)).tw,kf. 4 PCI.ti,ab. 5 ((balloon or stent*) adj3 angioplast*).tw,kf. 6 ((drug coated or drug eluting or drug releasing) adj3 stent*).tw,kf. 7 1 or 2 or 3 or 4 or 5 or 6 8 exp dual antiplatelet therapy/ 9 ((antiplatelet or anti-platelet) adj3 (dual or combination) adj3 (intervention* or therap*)).tw,kf. 10 DAPT.ti,ab. 11 ((Aspirin or Acetylsalicylic acid) and (clopidogrel or plavix or prasugrel or effient or ticagrelor or brilinta or P2Y12 inhibitor*)).tw,kf. 12 8 or 9 or 10 or 11 13 7 and 12 14 exp randomized controlled trial/ 15 exp single blind procedure/ 16 double blind procedure/ 17 crossover procedure/ 18 (random* or factorial* or crossover* or placebo* or assign* or allocat* or volunteer*).tw,kf. 19 (cross adj1 over).tw,kf. 20 ((double or triple or single) adj1 (mask* or blind*)).tw,kf. 21 14 or 15 or 16 or 17 or 18 or 19 or 20 22 13 and 21 23 treatment duration/ 24 ((duration or length or timing or time or months or reduce* or alterat*) adj3 (dose* or therap* or treatment* or medication* or DAPT or dual anti-platelet)).tw,kf. 25 (duration or length or timing or time or month*).ti. 26 (de-escalat* or prescribing practice* or short-term or abbreviat*).tw,kf. 27 prescribing practice/ 28 23 or 24 or 25 or 26 or 27 29 22 and 28
Ovid MEDLINE	1 exp Percutaneous Coronary Intervention/ 2 exp drug eluting stent/ 3 (percutaneous coronary adj3 (interven* or revascular*)).tw,kf. 4 PCI.ti,ab. 5 ((balloon or stent*) adj3 angioplast*).tw,kf. 6 ((drug coated or drug eluting or drug releasing) adj3 stent*).tw,kf.

	7 1 or 2 or 3 or 4 or 5 or 6 8 ((antiplatelet or anti-platelet) adj3 (dual or combination) adj3 (intervention* or therap*)).tw,kf. 9 DAPT.ti,ab. 10 ((Aspirin or Acetylsalicylic acid) and (clopidogrel or plavix or prasugrel or effient or ticagrelor or brilinta or P2Y12 inhibitor*)).tw,kf. 11 8 or 9 or 10 12 7 and 11 5188 13 "duration of therapy"/ 14 ((duration or length or timing or time or months or reduce* or alterat*) adj3 (dose* or therap* or treatment* or medication* or DAPT or dual anti-platelet)).tw,kf. 15 (duration or length or timing or time or month*).ti. 16 (de-escalat* or prescribing practice* or short-term or abbreviat*).tw,kf. 17 13 or 14 or 15 or 16 18 12 and 17 19 exp randomized controlled trial/ 20 single-blind method/ 21 Double-Blind Method/ 22 cross-over studies/ 23 (random* or factorial* or crossover* or placebo* or assign* or allocat* or volunteer*).tw,kf. 24 (cross adj1 over).tw,kf. 25 ((double or triple or single) adj1 (mask* or blind*)).tw,kf. 26 19 or 20 or 21 or 22 or 23 or 24 or 25 27 18 and 26
PubMed	((((random*[Title/Abstract] OR factorial*[Title/Abstract] OR crossover*[Title/Abstract] OR placebo*[Title/Abstract] OR assign*[Title/Abstract] OR allocat*[Title/Abstract] OR volunteer*[Title/Abstract])) OR (double mask*[Title/Abstract] OR double blind*[Title/Abstract] OR single mask*[Title/Abstract] OR single blind*[Title/Abstract] OR triple blind*[Title/Abstract] OR triple mask*[Title/Abstract] OR cross over[Title/Abstract])) OR (randomized controlled trial[MeSH Terms])) AND (((de-escalat*[Title/Abstract] OR prescribing practice*[Title/Abstract] OR short-term[Title/Abstract] OR abbreviat*[Title/Abstract] OR duration[Title/Abstract] OR length[Title/Abstract] OR timing[Title/Abstract] OR time[Title/Abstract] OR month*[Title/Abstract]) AND ((((Aspirin[Title/Abstract] OR Acetylsalicylic acid[Title/Abstract]) AND (clopidogrel[Title/Abstract] OR plavix[Title/Abstract] OR prasugrel[Title/Abstract] OR effient[Title/Abstract] OR ticagrelor[Title/Abstract] OR brilinta[Title/Abstract] OR P2Y12 inhibitor*[Title/Abstract]))) OR (DAPT[Title/Abstract] OR dual antiplatelet[Title/Abstract] OR dual anti-platelet[Title/Abstract]))) AND (percutaneous coronary interven*[Title/Abstract] OR percutaneous coronary revascular*[Title/Abstract] OR PCI[Title/Abstract] OR balloon angioplast*[Title/Abstract] OR stent* angioplast*[Title/Abstract] OR drug coated stent*[Title/Abstract] OR drug eluting stent*[Title/Abstract] OR drug releasing stent*[Title/Abstract]))
Scopus	(TITLE-ABS-KEY ((antiplatelet OR anti-platelet) W/3 (dual OR combination) W/3 (intervention* OR therap*)) OR TITLE-ABS-KEY ((aspirin OR "Acetylsalicylic acid") AND (clopidogrel OR plavix OR prasugrel OR effient OR ticagrelor OR brilinta OR "P2Y12 inhibitor*")) OR TITLE-ABS-KEY (dapt)) AND (TITLE-ABS-KEY ("percutaneous coronary" W/3 (interven* OR revascular*)) OR TITLE-ABS-KEY (pci) OR TITLE-ABS-KEY ((balloon OR stent*) W/3 angioplast*) OR TITLE-ABS-KEY (("drug coated" OR "drug eluting" OR "drug releasing") W/3 stent*)) AND (TITLE-ABS-KEY ((duration OR length OR timing OR time OR months OR reduce* OR alterat*) W/3 (dose* OR therap* OR treatment* OR medication* OR dapt OR "dual anti-platelet")) OR TITLE-ABS-KEY (de-escalat* OR "prescribing practice*" OR short-term OR abbreviat*) OR TITLE (duration OR length OR timing OR time OR month*)) AND (TITLE-ABS-KEY (random* OR factorial* OR crossover* OR placebo* OR assign* OR allocat* OR volunteer*) OR TITLE-ABS-KEY (cross W/1 over) OR TITLE-ABS-KEY ((double OR triple OR single) W/1 (mask* OR blind*)))
Web of Science Core Collection	#1 TS=("percutaneous coronary" near/3 (interven* or revascular*)) or TS=(PCI) or TS=((balloon or stent*) near/3 angioplast*) or TS=(("drug coated" or "drug eluting" or "drug releasing") near/3 stent*) #2 TS=((antiplatelet or anti-platelet) near/3 (dual or combination) near/3 (intervention* or therap*)) or TS=((Aspirin or "Acetylsalicylic acid") and (clopidogrel or plavix or prasugrel or effient or ticagrelor or brilinta or "P2Y12 inhibitor*")) or TS=(DAPT)

	#3 TS=((duration or length or timing or time or months or reduce* or alterat*) near/3 (dose* or therap* or treatment* or medication* or DAPT or "dual anti-platelet")) OR TS=(de-escalat* or "prescribing practice*" or short-term or abbreviat*) OR TI=(duration or length or timing or time or month*) #4 TS=(random* or factorial* or crossover* or placebo* or assign* or allocat* or volunteer*) OR TS=(cross near/1 over) OR TS=((double or triple or single) near/1 (mask* or blind*)) #5 #1 and #2 and #3 and #4

Supplemental Table S3. Baseline demographics of the selected trials

Abbreviated/Standard, %	HOST-IDEA	MASTER DAPT	TICO	SMART CHOICE	TWILIGHT	STOPDAPT-2	REDUCE	SMART-DATE
Age, year, mean	65.6/65.9	76.1/76.0	61.0/61.0	64.6/64.4	65.2/65.1	68.1/69.1	61.0/60.0	62.0/62.2
Female	27.0/25.2	30.7/30.8	21.0/20.0	27.3/25.8	23.8/23.9	21.1/23.5	17.4/22.7	25.1/24.1
BMI, kg/m^2, mean	–	27.3/27.4	24.9/24.9	24..5/24.7	28.6/28.5	24.4/24.2	–	24.3/24.5
Diabetes mellitus	40.5/37.4	32.9/34.3	27.0/27.0	38.2/36.8	9.4/10.5	39.0/38.0	21.6/19.5	26.9/28.1
Hypertension	73.3/73.5	76.9/78.2	50.0/51.0	61.6/61.3	72.6/72.2	73.7/74.0	50.7/50.7	49.9/48.7
Dyslipidemia	81.2/80.1	67.2/68.1	61.0/60.0	45.1/45.5	60.7/60.2	74.4/74.8	46.3/44.9	24.2/25.2
Current smoking	–	10.0/8.1	–	28.4/24.5	20.4/23.1	26.6/20.6	42.1/42.7	38.0/40.1
Family history	–	–	–	–	–	–	35.0/36.0	-
Chronic kidney disease	11.0/10.5	18.2/20.1	19.0/22.0	2.9/3.5	16.8/16.7	5.5/5.6	–	1.0/0.5
Peripheral vascular disease	1.9/1.9	–	–	–	6.9/6.8	6.4/6.6	–	-
Heart failure	–	–	–	–	–	7.7/7.1	–	-
Prior myocardial infarction	4.5/4.2	18.9/18.8	4.0/3.0	4.1/4.3	28.7/28.6	13.8/13.2	–	2.3/1.7
Prior PCI	13.2/14.1	25.9/26.0	–	11.5/11.8	42.3/42.0	33.5/35.1	11.7/9.8	4.9/3.9
Prior CABG		7.4/7.5	1.0/1.0	–	10.2/9.8	1.1/2.8	2.8/2.8	
Prior stroke	6.9/6.3	–	4.0/4.0	6.6/6.8	–	–	1.5/2.0	3.9/4.4
Prior bleeding	–	7.2/6.8	–	–	0.9/0.9	1.3/1.9	–	-
LVEF, %, mean	58.2/58.6	53.5/53.0	–	60.0/59.9	–	59.8/59.7	–	55.5/55.4
Multivessel disease	51.8/51.7	–	55.0/56.0	50.1/49.0	63.9/61.6	–	–	43.6/46.6
Clinical presentation								
Silent ischemia	43.4/46.3	10.7/12.0	–	–	6.6/6.3	–	–	-
Stable angina		40.2/40.6	–	41.8/41.8	29.5/28.0	62.3/61.4	–	-
Unstable angina	35.7/34.7	11.3/11.4	29.0/32.0	31.2/32.8	35.1/34.9	12.9/14.2	15.2/13.8	31.0/3.7
NSTEMI	20.9/19.0	25.9/24.4	35.0/32.0	16.0/15.4	28.8/30.8	5.4/6.6	35.6/41.0	31.5/31.4
STEMI	–	11.9/11.6	36.0/36.0	11.0/10.0	–	19.4/17.9	49.3/45.2	37.5/37.9

Supplemental Table S3. Baseline demographics of the selected trials (continued)

Abbreviated/Standard, %	GLOBAL LEADERS	IVUS-XPL	SECURITY	ISAR-SAFE	OPTIMIZE	I-LOVE-IT 2	RESET	EXCELLENT
Age, year, mean	64.9/64.8	63.0/64.0	64.9/69.5	67.2/67.2	61.3/61.9	60.4/60.0	62.4/62.4	63.0/62.4
Female	24.0/23.5	33.0/30.0	22.4/23.2	19.3/19.5	36.5/36.9	32.8/31.3	35.6/37.1	34.9/36.1
BMI, kg/m^2, mean	–	24.8/24.6	–	27.2/27.5	–	25.1/25.3	25.0/24.9	24.9/25.1
Diabetes mellitus	24.3/23.7	36.0/37.0	30.4/31.4	24.8/24.2	35.4/35.3	23.2/22.1	29.8/28.8	37.7/38.6
Hypertension	72.5/72.3	–	74.5/71.1	90.1/91.5	86.4/88.2	61.0/64.8	62.3/61.4	72.7/73.8
Dyslipidemia	63.3/65.3	68.0/65.0	65.4/60.8	87.5/87.4	63.2/63.7	25.3/23.4	57.7/59.9	75.2/76.3
Current smoking	2.6/2.6	25.0/24.0	20.5/24.4	14.6/15.3	18.6/17.3	36.6/38.3	25.2/22.8	27.4/25.8
Family history	–	–	–	–	41.3/42.8	6.3/5.1	–	–
Chronic kidney disease	13.4/13.1	–	–	–	7.4/5.8	–	–	0.8/1.2
Peripheral vascular disease	6.7/7.9	–	–	–	2.8/3.0	1.4/1.1	–	–
Heart failure	–	–	–	–	4.3/4.2	–	11.3/11.8	0.6/0.7
Prior myocardial infarction	22.9/23.6	5.0/4.0	21.2/20.1	25.9/24.5	34.6/34.8	17.2/15.8	1.8/1.6	6.5/3.7
Prior PCI	32.6/33.9	10.0/10.0	19.4/16.2	–	20.9/19.1	8.5/6.5	3.5/3.0	9.3/8.6
Prior CABG	–	3.0/2.0	5.6/5.4	7.7/7.5	7.1/8.2	0.4/0.4	0.2/0.6	–
Prior stroke	–	–	–	–	2.5/2.5	9.2/9.5	–	6.5/6.7
Prior bleeding	0.7/0.6	–	–	–	0.6/0.6	–	–	–
LVEF, %, mean	55.1/55.3	62.3/63.1	56.3/56.6	–	–	60.8/60.3	64.2/63.9	61.0/61.6
Multivessel disease	–	–	43.8/40.8	–	–	–	43.1/42.9	–
Clinical presentation								
Silent ischemia	–	–	–	10.9/11.3	8.6/9.2	3.0/4.0	–	48.9/48.0
Stable angina	48.9/49.9	51.0/51.0	61.6/61.6	48.6/47.8	59.8/58.6	14.3/15.1	44.5/46.3	
Unstable angina	12.9/13.2	34.0/33.0	38.4/38.4	21.5/21.9	–	58.0/56.5	40.8/39.9	48.5/48.4
NSTEMI	20.0/19.4	15/16	–	10.4/10.1	5.4/5.4	13.4/13.7	14.7/13.8	
STEMI	18.2/17.5		–	7.9/8.3	–	11.3/10.7		2.6/3.6

Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction

Supplemental Table S4. Definition of outcomes used in the trials

Trial	Net Adverse Clinical Events	Major Adverse Cardiovascular Events	Bleeding
HOST-IDEA	Cardiac death, target vessel MI, clinically driven TLR, stent thrombosis, BARC type 3 or 5 bleeding	N/A[a]	N/A[a]
MASTER DAPT	MACE, BARC type 3 or 5 bleeding	All-cause mortality, MI, stroke	Major or nonmajor clinically relevant bleeding
TICO	MACE, TIMI major bleeding	All-cause mortality, MI, stent thrombosis, stroke, TVR	TIMI major bleeding
SMART-CHOICE	N/A[a]	All-cause mortality, MI, stroke	BARC type 2-5 bleeding
TWILIGHT	N/A[a]	All-cause mortality, MI, stroke	BARC type 2, 3, or 5 bleeding
STOPDAPT-2	Cardiac death, MI, stent thrombosis, stroke, TIMI minor or major bleeding	Cardiac death, MI, stent thrombosis, stroke	TIMI minor or major bleeding
REDUCE	All-cause mortality, MI, stent thrombosis, stroke, TVR, BARC type 2, 3, or 5 bleeding	N/A[a]	BARC 2, 3, or 4 bleeding
SMART-DATE	N/A[a]	All-cause mortality, MI, stroke	N/A[a]
GLOBAL LEADERS	N/A[a]	All-cause mortality, MI, stroke, urgent TVR	BARC type 3 or 5 bleeding
IVUS-XPL	Cardiac death, MI, stroke, TIMI major bleeding	N/A[a]	N/A[a]
SECURITY	Cardiac death, MI, stroke, definite or probable stent thrombosis, BARC type 3 or 5 bleeding	Cardiac death, MI, stroke, definite or probable stent thrombosis	BARC type 3 or 5 bleeding
ISAR-SAFE	All-cause mortality, MI, stent thrombosis, stroke, TIMI major bleeding	N/A[a]	N/A[a]
OPTIMIZE	All-cause mortality, MI, stroke, major bleeding	N/A[a]	N/A[a]
I-LOVE-IT 2	All-cause mortality, MI, stroke, BARC type 3-5 bleeding	Cardiac death, target vessel MI, clinically indicated TLR	N/A[a]
RESET	Cardiac death, MI, stent thrombosis, ischemia-driven TVR, TIMI major bleeding	N/A[a]	TIMI minor or major bleeding
EXCELLENT	N/A[a]	All-cause mortality, MI, stroke, revascularization	N/A[a]

[a]Not applicable because this outcome was not reported in subgroup of patients with diabetes mellitus

Abbreviations: BARC, Bleeding Academic Research Consortium; MI, myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction; TLR, target lesion revascularization; TVR, target vessel revascularization

Supplemental Table S5. Risk of bias in the selected studies using the Cochrane Risk Assessment Tool

Trial	Random Sequence Generation (Selection Bias)	Allocation Concealment (Selection Bias)	Blinding of Participants and Personnel (Performance Bias)	Blinding of Outcome Assessment (Detection Bias)	Incomplete Outcome Data (Attrition Bias)	Selective Reporting (Reporting Bias)	Other Bias
HOST-IDEA	Low	Low	High	Low	Low	Low	Unclear
MASTER DAPT	Low	Low	Low	Low	Low	Low	Unclear
TICO	Low	Low	High	Low	Low	Low	Unclear
SMART CHOICE	Low	Low	High	Low	Low	Low	Unclear
TWILIGHT	Low	Low	Low	Low	Low	Low	Unclear
STOPDAPT-2	Low	Unclear	High	Low	Low	Low	Unclear
REDUCE	Low	Low	High	Low	Low	Low	High
SMART-DATE	Low	Low	High	Low	Low	Low	Unclear
GLOBAL LEADERS	Low	Low	Low	Low	Low	Low	Unclear
IVUS-XPL	Low	Low	High	Low	Low	Low	High
SECURITY	Low	Low	Unclear	Low	Low	Low	Unclear
ISAR-SAFE	Low	Low	Low	Low	Low	Low	Unclear
OPTIMIZE	Low	Low	High	Low	Low	Low	Unclear
I-LOVE-IT 2	Low	Unclear	Unclear	Unclear	Low	Low	High
RESET	Low	Low	High	Unclear	Low	Low	Unclear
EXCELLENT	Low	Low	High	Low	Low	Low	High

Supplemental Table S6. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria for each outcome

Outcome	Trials	Risk of Bias	Imprecision	Inconsistency	Indirectness	Publication Bias	Certainty
Net adverse clinical events	11	Moderate	Low	Low	Low	Low	⨁⨁⨁◯
Major adverse cardiovascular events	10	Moderate	Moderate	Low	Low	Low	⨁⨁⨁◯
Bleeding	9	Moderate	Moderate	Low	Low	Low	⨁⨁⨁◯
Definite or probable stent thrombosis	10	Moderate	Low	Low	Low	Low	⨁⨁⨁◯

Supplemental Table S7. Heterogeneity assessment in network meta-analysis

Outcome	τ^2	I^2
Net adverse clinical events	0	0%
Major adverse cardiovascular events	0.0490	42.1%
Bleeding	0.0297	14.6%
Definite or probable stent thrombosis	0	0%

Supplemental Table S8. Node-splitting analysis of inconsistency for each outcome

Outcome	Comparison	*K*	Prop	*NMA*	Direct	Indirect	Difference	*Z*-value	*P*-value
Net adverse clinical events	12 months versus 1 month	1	0.57	0.0916	0.1360	0.0320	0.1040	0.30	0.7617
	3 months versus 1 month	0	0	-0.1278	-	-0.1278	-	-	-
	6 months versus 1 month	1	0.76	-0.0141	-0.0390	0.0650	-0.1040	-0.30	0.7617
	12 months versus 3 months	5	1.00	0.2194	0.2194	-	-	-	-
	12 months versus 6 months	4	0.67	0.1057	0.0710	0.1750	-0.1040	-0.30	0.7617
	3 months versus 6 months	0	0	-0.1137	-	-0.1137	-	-	-
Major adverse cardiovascular events	12 months versus 1 month	2	0.75	0.0148	0.1047	-0.2591	0.3638	0.89	0.3747
	3 months versus 1 month	0	0	-0.1776	-	-0.1776	-	-	-
	6 months versus 1 month	1	0.50	0.1047	-0.0761	0.2877	-0.3638	-0.89	0.3747
	12 months versus 3 months	3	1.00	0.1924	0.1924	-	-	-	-
	12 months versus 6 months	4	0.74	-0.0900	-0.1831	0.1807	-0.3638	-0.89	0.3747
	3 months versus 6 months	0	0	-0.2823	-	-0.2823	-	-	-
Bleeding	12 months versus 1 month	2	0.91	0.4782	0.4368	0.8812	-0.4444	-0.46	0.6423
	3 months versus 1 month	0	0	0.1456	-	0.1456	-	-	-
	6 months versus 1 month	1	0.93	0.2383	0.2674	-0.1770	0.4444	0.46	0.6423
	12 months versus 3 months	5	1.00	0.3325	0.3325	-	-	-	-
	12 months versus 6 months	1	0.16	0.2399	0.6139	0.1695	0.4444	0.46	0.6423
	3 months versus 6 months	0	0	-0.0927	-	-0.0927	-	-	-
Definite or probable stent thrombosis	12 months versus 1 month	2	1.00	-0.1234	-0.1234	-	-	-	-
	3 months versus 1 month	0	0	-0.1779	-	-0.1779	-	-	-
	6 months versus 1 month	0	0	0.5786	-	0.5786	-	-	-
	12 months versus 3 months	5	1.00	0.0545	0.0545	-	-	-	-
	12 months versus 6 months	3	1.00	-0.7020	-0.7020	-	-	-	-
	3 months versus 6 months	0	0	-0.7565	-	-0.7565	-	-	-

Supplemental Table S9. Event rates of each outcome in the included trials

Outcome	Trial	Shortened DAPT	Control DAPT
Net adverse clinical events	HOST-IDEA	4.7%	7.1%
	MASTER DAPT	8.6%	8.3%
	TICO	6.2%	8.6%
	STOPDAPT-2	3.5%	4.1%
	REDUCE	11.1%	11.0%
	I-LOVE-IT 2	11.8%	9.4%
	IVUS-XPL	2.0%	3.1%
	SECURITY	3.9%	5.4%
	ISAR-SAFE	1.8%	2.5%
	OPTIMIZE	6.1%	6.7%
	RESET	3.5%	4.6%
Major adverse cardiovascular events	MASTER DAPT	7.3%	6.8%
	TICO	3.3%	5.0%
	GLOBAL LEADERS	10.1%	12.6%
	SMART CHOICE	4.0%	3.6%
	TWILIGHT	4.5%	5.8%
	STOPDAPT-2	3.2%	3.0%
	SMART-DATE	6.6%	7.4%
	I-LOVE-IT 2	10.0%	9.4%
	SECURITY	2.9%	3.6%
	EXCELLENT	8.9%	2.8%
Bleeding	MASTER DAPT	7.0%	9.2%
	TICO	2.9%	4.3%
	GLOBAL LEADERS	2.6%	3.0%
	SMART CHOICE	2.5%	2.9%
	TWILIGHT	4.4%	6.7%
	STOPDAPT-2	0.3%	1.5%
	REDUCE	3.1%	2.1%
	SECURITY	1.0%	1.8%
	RESET	0.0%	0.7%
Stent thrombosis	TICO	1.0%	0.7%
	GLOBAL LEADERS	2.5%	2.4%
	TWILIGHT	0.5%	0.7%
	STOPDAPT-2	0.5%	0.1%
	REDUCE	0.6%	1.4%
	I-LOVE-IT 2	0.5%	0.5%
	SECURITY	0.5%	0.4%
	OPTIMIZE	1.6%	1.1%
	RESET	0.0%	0.3%
	EXCELLENT	1.5%	0.0%

Abbreviations: DAPT, dual antiplatelet therapy

Supplemental Table S10. Sensitivity analysis of trials that reported major bleeding

Bleeding (5 trials included)	**1 month**			
	1.36 (0.43-4.30)	**3 months**		
	1.18 (0.15-9.38)	0.87 (0.11-6.58)	**6 months**	
	0.64 (0.27-1.52)	0.47 (0.22-0.99)	0.54 (0.8-3.55)	**12 months**

The duration of dual antiplatelet therapy at the rightmost column serves as the reference group for the respective column.

Supplemental Table S11. Sensitivity analysis excluding the OPTIMIZE trial

Net adverse clinical events (10 trials included)	**1 month**			
	1.20 (0.77-1.87)	**3 months**		
	1.01 (0.76-1.35)	0.85 (0.55-1.30)	**6 months**	
	0.91 (0.65-1.27)	0.76 (0.57-1.02)	0.90 (0.66-1.24)	**12 months**
Major adverse cardiovascular events (10 trials included)	**1 month**			
	1.19 (0.71-2.00)	**3 months**		
	0.90 (0.60-1.35)	0.75 (0.45-1.27)	**6 months**	
	0.99 (0.70-1.39)	0.82 (0.56-1.21)	1.09 (0.77-1.55)	**12 months**
Bleeding (9 trials included)	**1 month**			
	0.86 (0.45-1.65)	**3 months**		
	0.79 (0.50-1.25)	0.91 (0.42-1.96)	**6 months**	
	0.62 (0.36-1.07)	0.72 (0.51-0.99)	0.79 (0.40-1.56)	**12 months**
Definite or probable stent thrombosis (9 trials included)	**1 month**			
	1.54 (0.59-4.02)	**3 months**		
	0.56 (0.10-3.13)	0.36 (0.06-2.19)	**6 months**	
	1.13 (0.65-1.98)	0.73 (0.34-1.59)	2.02 (0.40-10.24)	**12 months**

The duration of dual antiplatelet therapy at the rightmost column serves as the reference group for the respective column.

Supplemental Table S12. Sensitivity analysis including trials that exclusively enrolled patients with acute coronary syndrome

Net adverse clinical events (3 trials included)	**1 month**			
	1.20 (0.62-2.33)	**3 months**		
	-	-	**6 months**	
	0.98 (0.57-1.68)	0.82 (0.55-1.20)	-	**12 months**
Major adverse cardiovascular events (3 trials included)	**1 month**			
	1.86 (0.76-4.54)	**3 months**		
	1.38 (0.62-3.06)	0.74 (0.32-1.73)	**6 months**	
	1.24 (0.68-2.25)	0.67 (0.34-1.29)	0.89 (0.53-1.51)	**12 months**

The duration of dual antiplatelet therapy at the rightmost column serves as the reference group for the respective column. For net adverse clinical events, pooled risk ratios associated with 6 months of dual antiplatelet therapy are not shown because of the absence of trials that included 6 months of dual antiplatelet therapy in their control group and reported major bleeding rates in men and women.

Supplemental Figure S1. Node-splitting analysis of inconsistency for each outcome

Net adverse clinical events



Major adverse cardiovascular events



Bleeding	
Definite or probable stent thrombosis